Introduction

The Doxotor 50 mg (Doxorubicin) Injection is a high-potency anthracycline chemotherapy agent designed for aggressive treatment regimens in advanced cancers, including ovarian cancer, AIDS-related Kaposi’s sarcoma, and multiple myeloma. Manufactured by Eskayef Pharmaceuticals Ltd., a leader in oncology innovation, and supplied globally by Onco Solution, this injection delivers concentrated efficacy to disrupt DNA synthesis and topoisomerase II activity, offering renewed hope for patients with refractory or high-risk malignancies.

Key Benefits

High-Dose Efficacy: 50 mg formulation enables potent tumor suppression with optimized dosing.

• DNA-Targeted Action: Intercalates with DNA and inhibits topoisomerase II, halting cancer cell replication.
• Versatile Application: Effective for ovarian cancer, Kaposi’s sarcoma, and myeloma in combination therapies.
• Global Accessibility: Supplied by Onco Solution, ensuring reliable access to critical therapies.

Indications

The Doxotor 50 mg (Doxorubicin) Injection is indicated for:

1. Advanced Ovarian Cancer: Post-failure of platinum-based chemotherapy.
2. AIDS-Related Kaposi’s Sarcoma: After intolerance or failure of prior systemic treatments.
3. Multiple Myeloma: Combined with bortezomib in patients with ≥1 prior therapy.

Pharmacology

• Mechanism of Action: Doxorubicin binds to DNA, disrupting replication and transcription, while inhibiting topoisomerase II, leading to apoptosis in rapidly dividing cancer cells.
• Cytotoxic Spectrum: Demonstrates broad activity against solid tumors and hematologic cancers, including multidrug-resistant strains.

Dosage & Administration

• General Guidelines:
  • Administer intravenously at 1 mg/min initially to mitigate infusion reactions; complete infusion over 1 hour if tolerated.
  • Avoid bolus injection or undiluted administration.
• Dosing by Indication:
  • Ovarian Cancer: 50 mg/m² every 3–4 weeks.
  • Kaposi’s Sarcoma: 20 mg/m² every 3 weeks.
  • Multiple Myeloma: 30 mg/m² on day 4 post-bortezomib.

Drug Interactions

• Antibiotics (Aminoglycosides): Increased nephrotoxicity risk.
• Steroids/Aminophylline: Potential synergistic toxicity.
• Propranolol: Altered drug metabolism; monitor closely.

Contraindications

• Severe cardiac impairment or prior mediastinal irradiation.
• Pregnancy, lactation, neonatal use, or severe myelosuppression.

Side Effects

Common Reactions:

• Hematologic: Leukopenia (80%), thrombocytopenia (60%).
• Gastrointestinal: Nausea (70%), vomiting (50%), diarrhea (40%).
• Dermatologic: Alopecia (90%), skin hyperpigmentation (20%).

Severe Risks:

• Cardiotoxicity: Cumulative cardiomyopathy (monitor LVEF regularly).
• Neurotoxicity: Peripheral neuropathy, seizures (rare).
• Hypersensitivity: Rash, anaphylaxis (premedicate with antihistamines).

Pregnancy & Lactation

• Pregnancy Category D: Contraindicated except in life-threatening scenarios.
• Lactation: Discontinue breastfeeding due to risks of infant toxicity.

Precautions & Warnings

• Hepatic Impairment:
  • Bilirubin 12–30 mcg/mL: Reduce dose by 50%.
  • Bilirubin >30 mcg/mL: Reduce dose by 75%.
• Cardiac Monitoring: Regular ECGs and echocardiograms for patients with cumulative doses >400 mg/m².
• Myelosuppression: Monitor CBC weekly; delay therapy if neutrophils <1,500 cells/mm³.

Overdose Management

• Symptoms: Severe myelosuppression, mucositis, heart failure.
• Treatment:
  • Hospitalization for supportive care (antibiotics, transfusions).
  • Administer G-CSF for neutropenia; manage heart failure with ACE inhibitors.

Storage Conditions

• Powder for Injection: Store at 15–30°C in original packaging.
• Reconstituted Solution: Refrigerate at 2–8°C; use within 24 hours.

Why Choose Doxotor 50 mg (Doxorubicin) Injection?

• Trusted Quality: Produced by Eskayef Pharmaceuticals Ltd., a WHO-GMP-certified manufacturer with 30+ years of excellence.
• Global Reach: Supplied by Onco Solution, ensuring equitable access across Asia, Africa, and Europe.
• Clinical Precision: High-dose formulation reduces administration frequency while maximizing efficacy.

Conclusion

The Doxotor 50 mg (Doxorubicin) Injection is a cornerstone of advanced oncology, offering potent DNA-targeted action for aggressive cancers. By integrating this high-dose therapy, clinicians leverage a solution backed by Eskayef Pharmaceuticals Ltd.’s rigorous standards and Onco Solution’s global distribution network, prioritizing both efficacy and patient safety.